Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.

Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...

Roche and Zealand Pharma have entered into a partnership worth up to $5.3bn to advance Zealand’s mid-stage obesity candidate petrelintide.

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

The agreement covering the compound petrelintide, announced by Roche on Wednesday, marks renewed efforts to catch up with weight-loss market leaders Novo Nordisk and Eli Lilly .

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...

Zealand Pharma partners with Roche on obesity drug petrelintide in $5.3B deal. Roche pays $1.4B upfront, plans combo studies with CT-388. Companies to split revenues in US/Europe.

Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from ...